Cornelis Melief wins 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research recognized Cornelis Melief with the seventh AACR-CRI Lloyd J. Old Award in Cancer Immunology during the AACR Annual Meeting 2019.

Melief is an emeritus professor at the Leiden University Medical Center in the Netherlands, as well as chief scientific officer at ISA Pharmaceuticals.

He is being recognized for his discovery of mechanisms of immune recognition of cancer antigens and activation of antitumor responses, and for his role in the development of innovative immunotherapies, including a vaccine against the human papillomavirus, a leading cause of cervical cancer. He currently focuses on developing new immunotherapies and improving their effectiveness through combination therapies.

As a member of the AACR, he served as a member of the Immunology Advisory Committee from 2005 to 2011, and as a member of the editorial board of the AACR journal Cancer Research.

Melief has been recognized with many scientific honors, including the SOFI Prize Leiden in 1986, the AkzoNobel Prize in 1995, the European Federation of Immunological Societies Lecture Award in 2007, the Ceppellini Lecture from the European Society of Immunogenetics in 2009, the William B. Coley Award from the Cancer Research Institute in 2009, and the Queen Wilhelmina Research Prize from the Dutch Cancer Society in 2010.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login